Cycloheptapyridine compounds, preparation method thereof, use and pharmaceutical compositions containing the compounds

Abstract

The invention provides a cycloheptane and pyridine compound as shown in formula I and pharmaceutically acceptable salt. The invention also relates to a preparation method for cycloheptane and pyridine compound as well as applications of the same in the preparation of the drugs for treating and preventing Alzheimer's disease, children's mental retardation syndrome, amnesia and other cardiovascular disease. The cycloheptane and pyridine compound can be used as alpha, beta, gamma-secretase agonist and / or inhibitors to prevent the production of beta-amyloid by agonizing or inhibiting enzyme activity so as to effectively treat and / or prevent Alzheimer's disease, children's mental retardation syndrome, amnesia and other cardiovascular disease.

Description

Cycloheptanepyridine compounds, their preparation method, use and pharmaceutical composition containing such compounds technical field The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, in particular to a novel cycloheptanepyridine compound, its preparation method, use and a pharmaceutical composition containing the compound. Background technique Among the refractory dementia cases, 50-70% are Alzheimer's Disease (AD). It is a degenerative disease of the brain, often with brain atrophy, especially the atrophy of the frontal cortex of the brain. Generally, the onset occurs after the age of 65 in men and 55 in women. In the early stage of the onset, it is only inattention and memory loss, which gradually develops to impoverished thinking, childish behavior, emotional instability, poor calculation ability, and incomprehension of other people's words. Finally, it becomes bedridden and completely loses the ability to live. With the ag...

AI Technical Summary

Problems solved by technology

However, the decline in cholinergic nerve function is a later change, so theoretically speaking, the use of cholinesterase inhibitors cannot exert a therapeutic effect on AD from an earlier stage

Images